Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma

Nalee Kim, Hyun Ju Kim, Jong Yun Won, Do Young Kim, Kwang Hyub Han, Inkyung Jung, Jinsil Seong

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and purpose: To evaluate the efficacy of stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods and materials: Patients treated for HCC between 2012 and 2016 were reviewed. Among these, 668 patients who underwent RFA of 736 tumors and 105 patients who underwent SBRT of 114 tumors were included. Using propensity score matching (PSM) to adjust for clinical factors, 95 tumors were selected from each treatment arm. Freedom from local progression (the primary endpoint, FFLP) was compared before and after adjustment with PSM. Results: At baseline, SBRT-treated tumors were more advanced, larger (median, 2.4 vs. 1.6 cm), and more frequently located in the subphrenic region than RFA-treated tumors (P <.001). The median follow-up was 21.5 (interquartile range, 11.2–36.7) months. Before PSM, the 2-year FFLP rates were 76.3% for the SBRT group and 70.2% for the RFA groups, respectively. After PSM, the 2-year FFLP rates were 74.9% for the SBRT group and 64.9% for the RFA group, respectively. The local control rates were not significantly different. The Cox proportional hazards model revealed the treatment modality as an independent predictor of local recurrence favoring SBRT in the entire cohort and in the PSM model. Elevated tumor markers, tumor location (subphrenic region), and tumor size (>2.0 cm) were also independent predictors of local progression. Conclusion: SBRT appears to be an effective alternative treatment for HCC when RFA is not feasible due to tumor location or size.

Original languageEnglish
Pages (from-to)81-87
Number of pages7
JournalRadiotherapy and Oncology
Volume131
DOIs
Publication statusPublished - 2019 Feb

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Radiosurgery
Neoplasms
Propensity Score
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{21a7a20c958e4bbfb98b434d882561e1,
title = "Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma",
abstract = "Background and purpose: To evaluate the efficacy of stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods and materials: Patients treated for HCC between 2012 and 2016 were reviewed. Among these, 668 patients who underwent RFA of 736 tumors and 105 patients who underwent SBRT of 114 tumors were included. Using propensity score matching (PSM) to adjust for clinical factors, 95 tumors were selected from each treatment arm. Freedom from local progression (the primary endpoint, FFLP) was compared before and after adjustment with PSM. Results: At baseline, SBRT-treated tumors were more advanced, larger (median, 2.4 vs. 1.6 cm), and more frequently located in the subphrenic region than RFA-treated tumors (P <.001). The median follow-up was 21.5 (interquartile range, 11.2–36.7) months. Before PSM, the 2-year FFLP rates were 76.3{\%} for the SBRT group and 70.2{\%} for the RFA groups, respectively. After PSM, the 2-year FFLP rates were 74.9{\%} for the SBRT group and 64.9{\%} for the RFA group, respectively. The local control rates were not significantly different. The Cox proportional hazards model revealed the treatment modality as an independent predictor of local recurrence favoring SBRT in the entire cohort and in the PSM model. Elevated tumor markers, tumor location (subphrenic region), and tumor size (>2.0 cm) were also independent predictors of local progression. Conclusion: SBRT appears to be an effective alternative treatment for HCC when RFA is not feasible due to tumor location or size.",
author = "Nalee Kim and Kim, {Hyun Ju} and Won, {Jong Yun} and Kim, {Do Young} and Han, {Kwang Hyub} and Inkyung Jung and Jinsil Seong",
year = "2019",
month = "2",
doi = "10.1016/j.radonc.2018.12.013",
language = "English",
volume = "131",
pages = "81--87",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. / Kim, Nalee; Kim, Hyun Ju; Won, Jong Yun; Kim, Do Young; Han, Kwang Hyub; Jung, Inkyung; Seong, Jinsil.

In: Radiotherapy and Oncology, Vol. 131, 02.2019, p. 81-87.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma

AU - Kim, Nalee

AU - Kim, Hyun Ju

AU - Won, Jong Yun

AU - Kim, Do Young

AU - Han, Kwang Hyub

AU - Jung, Inkyung

AU - Seong, Jinsil

PY - 2019/2

Y1 - 2019/2

N2 - Background and purpose: To evaluate the efficacy of stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods and materials: Patients treated for HCC between 2012 and 2016 were reviewed. Among these, 668 patients who underwent RFA of 736 tumors and 105 patients who underwent SBRT of 114 tumors were included. Using propensity score matching (PSM) to adjust for clinical factors, 95 tumors were selected from each treatment arm. Freedom from local progression (the primary endpoint, FFLP) was compared before and after adjustment with PSM. Results: At baseline, SBRT-treated tumors were more advanced, larger (median, 2.4 vs. 1.6 cm), and more frequently located in the subphrenic region than RFA-treated tumors (P <.001). The median follow-up was 21.5 (interquartile range, 11.2–36.7) months. Before PSM, the 2-year FFLP rates were 76.3% for the SBRT group and 70.2% for the RFA groups, respectively. After PSM, the 2-year FFLP rates were 74.9% for the SBRT group and 64.9% for the RFA group, respectively. The local control rates were not significantly different. The Cox proportional hazards model revealed the treatment modality as an independent predictor of local recurrence favoring SBRT in the entire cohort and in the PSM model. Elevated tumor markers, tumor location (subphrenic region), and tumor size (>2.0 cm) were also independent predictors of local progression. Conclusion: SBRT appears to be an effective alternative treatment for HCC when RFA is not feasible due to tumor location or size.

AB - Background and purpose: To evaluate the efficacy of stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods and materials: Patients treated for HCC between 2012 and 2016 were reviewed. Among these, 668 patients who underwent RFA of 736 tumors and 105 patients who underwent SBRT of 114 tumors were included. Using propensity score matching (PSM) to adjust for clinical factors, 95 tumors were selected from each treatment arm. Freedom from local progression (the primary endpoint, FFLP) was compared before and after adjustment with PSM. Results: At baseline, SBRT-treated tumors were more advanced, larger (median, 2.4 vs. 1.6 cm), and more frequently located in the subphrenic region than RFA-treated tumors (P <.001). The median follow-up was 21.5 (interquartile range, 11.2–36.7) months. Before PSM, the 2-year FFLP rates were 76.3% for the SBRT group and 70.2% for the RFA groups, respectively. After PSM, the 2-year FFLP rates were 74.9% for the SBRT group and 64.9% for the RFA group, respectively. The local control rates were not significantly different. The Cox proportional hazards model revealed the treatment modality as an independent predictor of local recurrence favoring SBRT in the entire cohort and in the PSM model. Elevated tumor markers, tumor location (subphrenic region), and tumor size (>2.0 cm) were also independent predictors of local progression. Conclusion: SBRT appears to be an effective alternative treatment for HCC when RFA is not feasible due to tumor location or size.

UR - http://www.scopus.com/inward/record.url?scp=85059193924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059193924&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2018.12.013

DO - 10.1016/j.radonc.2018.12.013

M3 - Article

C2 - 30773192

AN - SCOPUS:85059193924

VL - 131

SP - 81

EP - 87

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -